I have a strong background in cancer biology, molecular biology, immunology, and recombinant antibody engineering biotechnology, with over 10 years of experience in basic and translational breast cancer research. My expertise includes identifying and validating biomarkers that drive tumor progression through promoting cancer stem cell phenotype and an immunosuppressive tumor microenvironment (TME), identifying therapeutic targets for drug development, investigating molecular mechanisms of breast cancer aggressiveness, and evaluating the antitumor efficacy of therapeutic agents using preclinical models. My research has been focusing on exploring the roles of MAPK/JNK, MAPK/ERK, MELK, and AR signaling in triple-negative breast cancer and other breast cancer subtypes; define the impact of the immunosuppressive TME on breast cancer aggressiveness and tumor responses to chemotherapies and immunotherapies; and developing novel targeted immunochemotherapies.